Organization (Industry)
Aju Pharm (South Korea)
ClinicalTrials.gov lists Aju Pharm (South Korea) as lead sponsor of 19 trials. It has 17 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Aju Pharm (South Korea): 19 lead-sponsored trials and 1 legal-entity registration.
Disease areas (13)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dyslipidemias | 4 |
| Hypertension | 3 |
| Diabetes Mellitus | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Dry Eye Syndromes | 2 |
Showing 5 of 13 disease areas.
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 5 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 2 |
| 2015 | 1 |
Recruitment duration, a model prediction: none of the 19 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (17)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| AJU-S56 5% | Dry Eye Syndromes | Phase 3 | 2 |
| AJU-C52L, AJU-C52 | Essential Hypertension | Phase 3 | 1 |
| C52R1L, C52R1M | Hypertension | Phase 3 | 1 |
| C52R1L, C52R1M | Essential Hypertension | Phase 3 | 1 |
| AJU-C52L, AJU-C52 | Hypertension | Phase 3 | 1 |
Showing 5 of 17 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| B55R1 and B55R2 | 1 |
| OM-89 [Uro-Vaxom® Capsule] | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 4 of 4 hit target (n=4) | 3 of 4 on time (n=4) |
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes, obesity & metabolism | 1 |
| Integrative cancer therapies | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 2 | 2024-10-15 |
FDA warning letters (1)
| Issue date | Letter |
|---|---|
| 2025-05-21 | aju-pharm-co-ltd-704823-05212025 |
FDA recalls (8)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Fixone Hybrid Anchor | Class II | 2025-12-17 |
| Fixone Biocomposite Anchor | Class II | 2025-12-17 |
| Genesis Screw-In Anchor | Class II | 2025-12-17 |
| Genesis Dual Thread Screw-In Anchor | Class II | 2025-12-17 |
| Genesis Knotless Anchor | Class II | 2025-12-17 |
Showing 5 of 8 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2025-05-05 |
Latest dated events (34)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-17 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 34 events.
Biomarker capability evidence (12)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| GLB1 | Trial sponsor | Named in trial exclusion criteria |
| GLB1 | Trial sponsor | Named in trial exclusion criteria |
| KLK3 | Trial sponsor | Named in trial exclusion criteria |
| LORICRIN | Trial sponsor | Named in trial exclusion criteria |
| LRCH4 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 12 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda untitled letters, fda inspection record, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.